Multiple sclerosis trials in China

In China 28 Also abroad 503

28 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Hohhot, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xianyang, Yinchuan, Zhengzhou, Zunyi
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Beijing, Chengdu, Dongguan, Guangzhou, Jiazhuang, Shenyang
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
Phase 2Taking people
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
Where
Wuhan
Age
18 years to 65 years
People
100
Run by
Chuan Qin
See details and how to joinNCT07827716
Early phase 1Not yet taking people in China
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis
Where
Wuhan
Age
18 years to 65 years
People
12
Run by
Daishi Tian
See details and how to joinNCT07748637
Phase 2Taking people
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Where
Beijing
Age
18 years to 65 years
People
30
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07776743
Phase 1/2Not yet taking people in China
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis
Where
Wuhan
Age
18 years to 65 years
People
25
Run by
Tongji Hospital
See details and how to joinNCT07756268
Phase 1Taking people
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Where
Xi'an
Age
18 years to 75 years
People
9
Run by
Xijing Hospital
See details and how to joinNCT07587125
No phaseTaking people
Biomarkers in Autoimmune Disease of Nervous System
Where
Wuhan
Age
18 years and over
People
50,000
Run by
Tongji Hospital
See details and how to joinNCT06502015
Phase 1Not yet taking people in China
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Qingdao
Age
18 years to 70 years
People
18
Run by
The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266
No phaseTaking people
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Where
Guangzhou
Age
20 years to 55 years
People
100
Run by
Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07653984
No phaseTaking people
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Where
Beijing
Age
16 years to 75 years
People
1,000
Run by
Beijing Tiantan Hospital
See details and how to joinNCT04106830
Early phase 1Taking people
This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis
Where
Hubei
Age
18 years and over
People
9
Run by
Daishi Tian
See details and how to joinNCT07303790
No phaseNot yet taking people in China
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
Where
Beijing
Age
18 years to 75 years
People
75
Run by
Beijing GoBroad Hospital
See details and how to joinNCT07593911
Early phase 1Taking people
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Where
Wuhan
Age
18 years to 70 years
People
36
Run by
Tongji Hospital
See details and how to joinNCT07337785
Phase 1Taking people
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Where
Wuhan
Age
18 years to 75 years
People
6
Run by
Tongji Hospital
See details and how to joinNCT07526493
Phase 1Not yet taking people in China
A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.
Where
Wuhan
Age
18 years to 65 years
People
24
Run by
Daishi Tian
See details and how to joinNCT07523100
Early phase 1Not yet taking people in China
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
15
Run by
Tianjin Huanhu Hospital
See details and how to joinNCT07392528
No phaseNot yet taking people in China
Tongji NADs Cohort
Where
Wuhan
Age
18 years to 80 years
People
1,550
Run by
Tongji Hospital
See details and how to joinNCT07333196
No phaseTaking people
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Where
Guangzhou
Age
18 years and over
People
80
Run by
Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07353216
No phaseEnrolling by invitation
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
Where
Beijing
Age
6 years to 90 years
People
10,000
Run by
Beijing Tiantan Hospital
See details and how to joinNCT06643858
Early phase 1Taking people
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Tianjin Huanhu Hospital
See details and how to joinNCT06939166
No phaseTaking people
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
Where
Beijing
Age
18 years to 60 years
People
128
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT07087873
Phase 1Taking people
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
RenJi Hospital
See details and how to joinNCT06249438
No phaseTaking people
Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
Where
Beijing
Age
18 years to 65 years
People
85
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT06968039
Early phase 1Not yet taking people in China
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Where
Beijing
Age
18 years to 75 years
People
25
Run by
Xuanwu Hospital, Beijing
See details and how to joinNCT06485232